Rationale: Single-center randomized controlled trials of the Zephyr endobronchial valve (EBV) treatment have demonstrated benefit in severe heterogeneous emphysema. This is the first multicenter study evaluating this treatment approach.
Chronic obstructive pulmonary disease is a progressive, life-threatening, lung disease characterized by airflow obstruction that results in breathlessness and predisposes afflicted individuals to exacerbations and serious illness (1) . Patients with advanced emphysema remain one of the most at-risk subpopulations. It is estimated that more than 300 million people globally have chronic obstructive pulmonary disease, with considerable dyspnea caused by lung hyperinflation, poor quality of life, few treatment options, and a reduced life expectancy (2) (3) (4) .
Lung volume reduction surgery (LVRS) results in improvements in lung function, dyspnea, exercise tolerance, and long-term survival in appropriately selected patients with emphysema (5) (6) (7) (8) . Although LVRS has proven effective in selected populations, the technique is relatively underused because of concerns about the invasiveness of the procedure, morbidity, and the narrow patient eligibility criteria (9, 10) . Zephyr endobronchial valves (EBV; Pulmonx Corporation, Redwood City, CA) are one-way valves inserted via the bronchoscope into the airways of emphysematous lung, and are designed to cause lung deflation (and hence a reduction in hyperinflation) by allowing air and secretions out but preventing air entry.
Bronchoscopic lung volume reduction with Zephyr EBVs aims to provide the benefits seen with LVRS but with a reduction in morbidity. The VENT (Valves for Emphysema Palliation Trial) study achieved statistical but not clinically meaningful improvements in FEV 1 and 6-minute-walk distance (6MWD) between EBV-treated and control groups (11) , with post hoc analysis showing that improvements in these outcomes were clinically meaningful only in patients with no collateral ventilation (CV) between the target and ipsilateral lobes (11, 12) . Zephyr EBVs have been shown to cause target lobe volume reduction (TLVR) in patients without CV and where lobar occlusion is achieved (13, 14) . Clinically and statistically meaningful benefits in multiple outcome measures have been demonstrated in patients with heterogeneous (15, 16) and homogeneous emphysema (16, 17) . Two single-center randomized controlled trials (RCTs) (15, 16) have reported significant benefits of Zephyr EBVs over best medical care, and we now report the first multicenter study in patients with heterogeneous emphysema and without CV. Some of the results of this study have been previously reported in the form of an abstract (18) .
Methods Study Conduct
This RCT enrolled patients between June 2014 and June 2016 at 17 sites across Europe. The study was approved by the respective ethics committees at each site, and conducted in accordance with the Declaration of Helsinki (19) . All participating subjects provided written informed consent.
Study Subjects
Eligible subjects were ex-smokers greater than or equal to 40 years of age with severe emphysema. Key inclusion criteria were post-bronchodilator FEV 1 of between 15% and 45% predicted despite optimal medical management, total lung capacity greater than 100% predicted, residual volume (RV) greater than or equal to 180% predicted, and a 6MWD of between 150 and 450 m (complete criteria provided in Section E1 in the online supplement). High-resolution computed tomography scans were analyzed at an independent imaging core laboratory using quantitative software (VIDA Diagnostics, Coralville, IA) to measure lobar volumes and emphysema destruction by lobe. Heterogeneous emphysema was defined as a greater than 10% difference in destruction scores between target and ipsilateral lobes.
Eligible patients underwent Chartis (Pulmonx Corporation, Redwood City, CA) assessment to determine the presence of CV between target and adjacent lobes before randomization. The Chartis Pulmonary Assessment System is a validated system designed to assess for the presence of CV Sponsored and funded by Pulmonx Corporation, Redwood City, California.
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Correspondence and requests for reprints should be addressed to Samuel V. Kemp within isolated lung units. It consists of a Chartis console connected to a balloon catheter with a central channel that is used to occlude the target lobe, and to subsequently measure pressure and flow to calculate resistance to airflow in that lobe, and hence to quantify CV (13) . Figure E1 shows examples of CV-negative and CV-positive read-outs. Subjects who had a CV-negative target were randomized in a 2:1 fashion (blocked design and concealed envelopes) immediately after the Chartis measurement into either the EBV group or the standard of care alone (SoC) group. The bronchoscopy procedure for subjects randomized to SoC was terminated and subjects recovered appropriately as per institutional standards. Subjects randomized to the EBV group underwent immediate placement of Zephyr EBVs with the intention of complete lobar occlusion (12, 20) . Subjects assessed to be CV-positive were excluded (see Sections E2 and E3 for complete details).
Where there was more than one potential target lobe, the lobe with the highest destruction score and lowest perfusion as determined by scintigraphy was assessed for CV first. If the primary target lobe was CV-positive, or if the CV status was not assessable, then the secondary target lobe was evaluated (for further information, see Figure E2 ).
Follow-up
Subjects randomized to SoC were discharged after standard postbronchoscopy recovery, unless the treating physician deemed an admission necessary. Subjects randomized to EBVs were hospitalized for at least 1 day and discharged following a chest radiograph if there were no complications/serious adverse events (SAEs). Subjects were instructed to seek immediate medical attention in the event of symptoms of a potential pneumothorax. EBV subjects were evaluated at 45 days with a high-resolution computed tomography scan to assess TLVR, and to verify whether complete lobar occlusion had been achieved. If necessary (TLVR ,50%, or incomplete lobar occlusion), a repeat bronchoscopy and valve revision/replacement was performed.
Outcome Measures
All subjects were assessed at 3 months postbronchoscopy (SoC and EBV). For EBV subjects who underwent valve replacement or revision based on their 45-day high-resolution computed tomography scan, follow-up occurred 3 months after the revision bronchoscopy. Subjects in the SoC group were given the option of exiting the study following the 6-month evaluation if they wished to pursue EBV treatment, or to continue in follow-up until 12 months. Follow-up of the EBV group will continue to 24 months (see study scheme, Figure E3 ).
The primary endpoint was the percentage of subjects in the EBV group at 3 months post-procedure who had an improvement in the post-bronchodilator FEV 1 of greater than or equal to 12% (protocol-defined minimal clinically important difference [MCID]) compared with the percentage of subjects in the SoC group.
Secondary endpoints included comparison between EBV and SoC groups for the absolute and percent changes and responder rates (percentage of subjects achieving the MCID) at 3 and 6 months for FEV 1 (>12%), RV (<2430 ml), St. George's Respiratory Questionnaire (SGRQ) score (<24 points), 6MWD (>26 m), modified Medical Research Council dyspnea score (<21 point), and for the EBV group only, the absolute and percentage change in TLVR at 45 days post-procedure and the percentage of subjects meeting the TLVR MCID of greater than or equal to 350 ml (12) relative to baseline. Safety was assessed through review of all adverse events solicited at all scheduled or unscheduled visits.
Statistical Analyses
The sample size calculation of 78 subjects was based on proportions for the primary endpoint of 12% or greater improvement in FEV 1 at 47% (EBV) and 13% (SoC) estimated from the VENT study (11), a 2:1 randomization, 80% power, a = 0.05, a twosided chi-square test, and 15% drop-out rate. For the intention-to-treat (ITT) analysis, missing data were imputed using the last observation carried forward method. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). Absolute and percent changes from baseline were analyzed using a fixed-effect one-way analysis of variance (or analysis of covariance with baseline as a covariate) model for normally distributed data; otherwise the Wilcoxon rank sum test was used. Categorical variables were analyzed using a chi-square test. Section E4 provides details of the analysis populations.
Results
Two hundred and seventy-three subjects were screened, with 125 subjects meeting the inclusion/exclusion criteria. A total of 97 subjects deemed to be CV-negative were randomized, 65 subjects to EBVs and 32 to SoC (see CONSORT diagram, Figure E4 ). The median (range) number of randomized subjects per center was 5 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Baseline characteristics were similar in both groups, although the EBV group reported a worse respiratory-related quality of life (P = 0.042) and absolute but not percent predicted FEV 1 (P = 0.008) ( Table 1 ; see Table E1 ).
Treatment Details
A median of four valves (range, 2-8) per subject were implanted in the 65 EBV subjects. Treatment distributions were 52% left upper lobe, 22% left lower lobe, 15% right upper lobe, 8% right upper and right middle lobe combined, and 3% right lower lobe. The median hospital stay for the treatment visit was 4 days (range, 1-49) for the EBV group and 1 day (range, 1-3) for the SoC group. At 45 days post-procedure, 89.8% of subjects achieved a TLVR of greater than or equal to 350 ml, with a mean 6 SD of 1.09 6 0.62 L (P , 0.001). Individual subject TLVR changes are provided in Figure E5 . Eighteen subjects underwent a repeat bronchoscopy, 17 of whom had a revision procedure, and 12 of those subsequently developed significant TLVR.
Primary Outcome
At 3 months post-procedure, responder rates (>12% improvement from baseline in FEV 1 ) in the ITT population were 55.4% in the EBV group and 6.5% in the SoC group (P , 0.001), and for the per protocol (PP) population were 66.7% and 6.7%, respectively (P , 0.001). These differences were maintained at 6 months: ITT (EBV vs. SoC) 56.3% versus 3.2% (P , 0.001), and PP 66.3% versus 3.3% (P , 0.001), respectively ( Figure 1 ).
Secondary Outcomes
Statistically and clinically significant improvements from baseline were seen at both 3 and 6 months in the EBV group compared with the SoC group for FEV 1 (Figure 2A ), 6MWD ( Figure 2B ), and SGRQ score ( Figure 2C ). There was a ORIGINAL ARTICLE decrease in RV (P , 0.001) ( Figure 2D ) and BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) index (points; P , 0.001) ( Figure 2E ) in the EBV versus SoC group at both 3 and 6 months. The absolute and percent changes from baseline at 6 months are summarized in Table 2 . Changes from baseline for EBV and SoC groups and differences between groups for the changes for the PP population are provided in Tables E2-E9. For each outcome measure, a significantly greater number of subjects in the EBV group met or exceeded the MCID (Table 3 ; see Table E10 , Figures E6-E8) . In post hoc analysis, 76.9% of the ITT population and 90.2% of the PP population achieved the MCID for at least one of FEV 1 , 6MWD, and SGRQ at 6 months. Following the 6-month evaluation, 30 of the 32 SoC subjects exited the study and opted for EBV treatment.
Safety Outcomes
At 6 months, there were 44 respiratoryrelated SAEs in 31 (47.7%) subjects in the EBV group compared with four events in three (9.4%) subjects in the SoC group (P , 0.001; Fisher test), with most events occurring within 30 days of the procedure (Table 4 ). In the EBV group, the most common SAE was pneumothorax, which was managed according to a protocolized pneumothorax management flow chart (21) (see Figure E9 ). Other respiratory-related SAEs during the first 30 days in the EBV group included dyspnea (7.7%), chronic obstructive pulmonary disease exacerbation (4.6%), and pneumonia (4.6%). A summary of all respiratory and nonrespiratory adverse events is provided in Tables E11  and E12 . Heterogeneity index was assessed as the difference in the emphysema score between the target and the ipsilateral lobe. ‡ SGRQ scores range from 0 to 100, with higher scores indicating worse quality of life.
x mMRC dyspnea score scale ranges from 0 to 4, with higher scores indicating more severe dyspnea. jj BODE index score ranges from 0 to 10 based on a multidimensional scoring system to include FEV 1 , BMI, 6-minute-walk distance, and the mMRC dyspnea score. Higher scores denote a greater risk of mortality. ¶ Wilcoxon signed rank test. 
Pneumothorax
Over the 6-month follow-up period, there were 20 pneumathoraces in 19 of 65 (29.2%) EBV subjects, with a median time to onset of 1 day. Table E13 shows pneumothorax rate by lobe treated. In 14 subjects, the pneumothorax required an intervention and/or hospitalization and was therefore considered a SAE. Pneumothorax was managed by observation only in eight cases, and placement of chest drains in 11 cases. In one case, the air leak was addressed surgically. Seven subjects underwent a second bronchoscopy for an adverse event, five for valve removal for pneumothorax management, one for valve replacement a day after the initial procedure because of expectoration of a valve, and one for loss of effect. One EBV subject died of in-hospital cardiac arrest as a complication of pneumothorax. There were no differences in any outcome measure at 3 or 6 months in the EBV cohort between subjects who experienced a pneumothorax (n = 19) and those that did not (n = 46) (see Tables E14  and E15 ).
Discussion
This is the first multicenter, prospective RCT of Zephyr EBV treatment in patients with severe heterogeneous emphysema and absence of CV. We found statistically and clinically significant improvements in lung function, exercise capacity, and quality of life associated with Zephyr EBV treatment compared with standard of care. Ninety percent of subjects experienced TLVR, indicating appropriate selection of CV-negative patients and effective occlusion of the target lobe following EBV placement. Of significance, the EBV group had improvements that exceeded the MCIDs for FEV 1 , SGRQ, RV, 6MWD, and modified Medical Research Council at 6 months post-treatment. Post hoc analysis of the VENT study (11, 12) demonstrated the critical importance of the absence of CV and achieving complete lobar occlusion as necessary elements for successful lung volume reduction with EBVs. Although visual evaluation of fissure completeness has been useful in patient selection for bronchoscopic lung volume reduction with Zephyr EBVs (15), the physiologic assessment of air flow using the Chartis system has been more reliable (13, 16) . Using this approach, Klooster and coworkers (16) successfully demonstrated significant improvements in lung function and exercise capacity in patients with severe emphysema characterized by an absence of CV. Similarly, Valipour and coworkers (17) reported benefits in patients with homogeneous emphysema. The findings of the present multicenter RCT provide further confirmation that patients carefully selected for absence of CV experience significant, meaningful reduction in treated lobar volumes (mean, 1.09 6 0.62 L; P , 0.001) with benefits in lung function, dyspnea, exercise capacity, and quality of life following Zephyr EBV placement.
The magnitude of benefits seen in this study is comparable with those observed after LVRS (8), but with reduced morbidity. The mean change presented here in the 6MWD, a patient-centered outcome, is three times the MCID, and similar to values reported from a single center RCT (16) . Zephyr EBV treatment has the added benefits of being suitable for both upper and lower lobe disease and homogeneous disease (17) , and is a reversible procedure. Valves were permanently removed in seven subjects in our study with no associated complications.
There were a greater number of SAEs in the early post-procedure period (within the first 30 d) in the EBV group than in the SoC group (Table 4) . Pneumothorax was the most common adverse event, and was managed according to published guidelines (21) . The occurrence of pneumothoraces and air leaks is a common side effect of thoracic procedures, ranging from 4% to 42% after computed tomography-guided biopsy (22, 23), 11.6% for endobronchial coil treatment (24) , and up to 90% of patients within 30 days of LVRS (25) . The frequency of pneumothorax in the present study (21.5%) was similar to other published Zephyr EBV treatment studies (16, 17) , and the occurrence of pneumothorax does not seem to negatively impact clinical outcomes (26) . Of note, 94% (30 of 32) of the control subjects opted to exit the study and receive Zephyr EBV treatment after the 6-month evaluation. Previous retrospective analyses have demonstrated a survival advantage where TLVR is achieved after Zephyr EBV placement (27) (28) (29) . A reduction of more than 1 point in the BODE index has been associated with a significant decrease in mortality (30, 31) and the difference between groups in the change in BODE index in this prospective trial was 21.8 points. This is compatible with the recent report by Klooster and coworkers (32) , and raises the hope of improved survival in our subjects. This needs to be confirmed in future studies and with longer follow up data.
One limitation of this study is the follow-up out to only 6 months, although earlier single-center RCTs have reported 1-year follow-up data, demonstrating the durability of this treatment (33, 34) . Subjects in the EBV group will be followed out to 2 years, important for capturing events that may be infrequent in a 6-month window, such as exacerbations or mortality. Another limitation is the absence of a sham bronchoscopy in the SoC group, because the treatment involves an intervention with associated adverse events and the potential for a placebo effect. However, unlike other interventional devices for bronchoscopic lung volume reduction, the benefit of EBV treatment using a sham control has previously been demonstrated (15) , and patients in the SoC arm in our study did undergo bronchoscopy for the purposes of Chartis examination (although this does not mitigate against any placebo effect associated with actual valve implantation).
Another potential limitation is the lack of mandatory pulmonary rehabilitation in the period before trial entry. Given the randomized nature of the trial, any changes or lack thereof associated with the potentially variable provision of preprocedure pulmonary rehabilitation should be balanced across the two groups, and therefore would not be expected to be a significant factor in any between-group differences.
Although there was an apparent imbalance in the absolute FEV 1 , and to a lesser extent SGRQ, at baseline between the two groups (although not in the percent predicted FEV 1 ), which could have affected outcome, analysis of covariance models with baseline values as the covariate resulted in the same P values as when using the Student's t test for all secondary endpoints, indicating that the group differences (EBV vs. SoC) are there despite the groups having different baseline values.
The benefits of EBV treatment for patients with severe heterogeneous emphysema reported here, and for homogeneous patients previously reported by Valipour and coworkers (17) , demonstrate that EBV placement is an effective treatment option in patients without CV regardless of emphysema distribution. The success of the treatment requires accurate patient selection including correct determination of the absence of CV between target and adjacent lobes, and expertise in the management of procedural complications. 
